Skip to content

B & V PHARMA

Active Private limited companyfounded 2005active for 20 yearsHortweidenweg 52, 3520 ZonhovenKBO/BCE: BE 0877.584.833

Board

2 directors, last change in 2023
Director (not named in the articles)
since 19-10-2022 term without a fixed end
earlier manager, until 26-01-2023
listed in the 2025 annual accounts, filed on 18-06-2026
Director (not named in the articles)
since 19-10-2022 term without a fixed end
earlier manager, until 26-01-2023
listed in the 2025 annual accounts, filed on 18-06-2026
Signing authorityThe articles say who may bind the company, for example by signing a contract.
Each director alone
deed of 26-01-2023

Office holders in the KBO →

Mandates through the years

2 names, the dashed line is today

Director (not named in the articles)

Director (not named in the articles)
BoardEarliermandate already running before its first mention
Mandates as a list
    • Director (not named in the articles), since before 31-12-2021
    • Manager, until 26-01-2023
    • Director (not named in the articles), since before 31-12-2021
    • Manager, until 26-01-2023
With Starter you also see 1 former office holder in the mandate history. See the plans →

Control

Shareholders
, ,
This company
B & V PHARMA
Equity €939,237
Profit €213,775 in 2025

Capital

Contribution
€6,200
Source
2025 annual accounts

Articles of association

deed of 26-01-2023 (in Dutch)
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
First Friday of June at 20:00

Shareholders

Stated in the deed deed of 25-03-2014 ↗
  • 4 shares
  • 4 shares
  • 786 shares

Capital transactions

Capital over time
  1. 26-01-2023 Converted to unavailable equity
  2. 25-01-2018 Capital reduction of €369,000 · to €18,600
  3. 25-03-2014 Capital increase of €369,000 · to €387,600 · 794 new shares · “inbreng zekere vaststaande opeisbare schuldvordering 90 procent vordering uitkering tussentijds dividend”

Next steps